Editorial Board member, Eleni Andreopoulou, spoke to us at the 2019 ASCO annual meeting about the advances made in immunotherapy for the treatment of breast cancer.
In Part 2 Eleni discusses promising combined immunotherapeutic regimens and how we can identify patients that could benefit from this type of therapy.
Questions
1. What combined immunotherapeutic regimens appear to be most promising in breast cancer? (0:04)
2. How can we select patients who are most likely to respond to combined immunotherapy approaches? (3:57)
Speaker disclosure: Eleni Andreopoulou has nothing to disclosure in relation to this video interview.
Filmed at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, Chicago, IL, USA.
